Arcus Biosciences Inc (RCUS)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -283,000 | -270,000 | -249,000 | -231,000 | -307,000 | -293,000 | -287,000 | -279,000 | -267,000 | 79,538 | 66,563 | 57,593 | 53,000 | -278,391 | -198,594 | -167,698 | -122,858 | -87,603 | -111,777 | -94,793 |
| Total stockholders’ equity | US$ in thousands | 485,000 | 565,000 | 635,000 | 707,000 | 462,000 | 520,000 | 566,000 | 600,000 | 657,000 | 699,000 | 747,000 | 797,000 | 842,000 | 542,607 | 604,555 | 664,790 | 502,000 | 544,417 | 428,710 | 140,638 |
| ROE | -58.35% | -47.79% | -39.21% | -32.67% | -66.45% | -56.35% | -50.71% | -46.50% | -40.64% | 11.38% | 8.91% | 7.23% | 6.29% | -51.31% | -32.85% | -25.23% | -24.47% | -16.09% | -26.07% | -67.40% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-283,000K ÷ $485,000K
= -58.35%
Arcus Biosciences Inc's return on equity (ROE) has shown significant fluctuation over the analyzed periods. The company experienced negative ROE values for the majority of the time, indicating that it was not effectively generating profits from its shareholders' equity.
However, there were notable improvements in ROE for the periods ending December 31, 2021, March 31, 2022, June 30, 2022, and September 30, 2022, where the ROE turned positive. This suggests that the company managed to generate higher profits relative to its equity during these quarters.
Unfortunately, the positive trend was not sustained, as the ROE values turned negative again from December 31, 2022, onwards. The ROE trend worsened in the later periods, particularly in the quarters ending September 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024, with progressively lower negative values.
Overall, Arcus Biosciences Inc's ROE performance indicates inconsistent profitability in relation to its equity over the analyzed periods, with a mix of positive and negative values.
Peer comparison
Dec 31, 2024